Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Sunday 05.04.2020 at 10:00 AM CEST
Settings

Settings

1. WO1996005292 - ANTIGENICALLY-MARKED NON-INFECTIOUS RETROVIRUS-LIKE PARTICLES

Publication Number WO/1996/005292
Publication Date 22.02.1996
International Application No. PCT/CA1995/000483
International Filing Date 15.08.1995
Chapter 2 Demand Filed 25.01.1996
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
C07K 14/11 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C12N 7/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C12N 7/04 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
CPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C07K 2319/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
C12N 2740/16023
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16023Virus like particles [VLP]
C12N 2740/16122
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16222
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16211concerning HIV gagpol
16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West Willowdale, Ontario M2R 3T4, CA (AllExceptUS)
  • ROVINSKI, Benjamin [CA/CA]; CA (UsOnly)
  • CAO, Shi-Xian [CN/CA]; CA (UsOnly)
  • YAO, Fei-long [CN/CA]; CA (UsOnly)
  • PERSSON, Roy [CA/CA]; CA (UsOnly)
  • KLEIN, Michel, H. [CA/CA]; CA (UsOnly)
Inventors
  • ROVINSKI, Benjamin; CA
  • CAO, Shi-Xian; CA
  • YAO, Fei-long; CA
  • PERSSON, Roy; CA
  • KLEIN, Michel, H.; CA
Agents
  • STEWART, Michael, I.; Sim & McBurney Suite 701 330 University Avenue Toronto, Ontario M5G 1R7, CA
Priority Data
08/290,10515.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGENICALLY-MARKED NON-INFECTIOUS RETROVIRUS-LIKE PARTICLES
(FR) PARTICULES RETROVIRIFORMES NON INFECTIEUSES A MARQUAGE ANTIGENIQUE
Abstract
(EN)
Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. In a further embodiment, the marker comprises modification of an immunodominant region of the env gene product to substantially prevent recognition of the immunodominant region. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in $i(in vivo) administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.
(FR)
Des particules rétroviriformes non infectieuses comportent un ensemble d'un produit génique env, un produit génique pol et un produit génique gag contiennent un marqueur antigénique non rétroviral ou non du type VIH. Dans un mode de réalisation, le marqueur comporte une séquence aminoacide contenant un épitope inséré dans le produit génique gag au niveau d'un site d'insertion à action antigénique. Dans un autre mode de réalisation, le marqueur comprend une séquence d'ancrage antigénique en liaison fonctionnelle avec le produit génique env remplaçant la fonction d'ancrage endogène. Dans un autre mode de réalisation, le marqueur comprend une modification d'une région immunodominante du produit génique env pour empêcher sensiblement la reconnaissance de cette région immunodominante. Les molécules d'acide nucléique correspondantes sont décrites. Ces particules rétroviriformes non infectieuses sont utiles pour l'administration $i(in vivo), notamment chez l'homme, et pour le diagnostic. La présence du marqueur antigénique permet la reconnaissance du fait que l'antisérum contenant des anticorps antirétroviraux a été produit par exposition aux particules rétroviriformes non infectieuses lors de la recherche d'anticorps spécifiques du marqueur antigénique.
Latest bibliographic data on file with the International Bureau